卵巢癌一线治疗中11种循环miRNA与CA125动力学的预测价值比较分析(GINECO研究)
基于CHIVA随机II期试验的119例卵巢癌患者系列血样,评估11种miRNA与CA125在化疗期间的动力学变化及其对IDS完全切除可能性和生存的预后/预测价值。miRNA纵向表达高度不一致,与CA125动态无关,新辅助治疗期间miRNA变化与RECIST肿瘤反应或IDS结局无关联;单变量分析中miR-34a-5p下降与PFS获益相关(p=.009),miR-93-5p下降与OS获益相关(p<.001)。
要点
- 11种miRNA纵向表达高度不一致,与CA125动态无关。
- 新辅助治疗期间miRNA变化与RECIST反应或IDS结局无关联。
- 单变量分析中miR-34a-5p下降与PFS获益相关(p=.009)。
核心结论
- 卵巢癌新辅助治疗期间miRNA纵向表达动力学不一致,未发现与肿瘤负荷变化相关。
- 虽可讨论某些预后价值,但未发现对肿瘤反应或IDS质量的预测价值。
研究设计与样本
- 基于随机II期CHIVA试验(NCT01583322)的系列血样分析,比较一线卡铂-紫杉醇±尼达尼布联合IDS患者中11种miRNA与CA125的动力学。
- 共分析119例患者的756份系列血样,完成8172次miRNA检测和1299次CA125值。
- miRNA选择基于大型探索性面板的表达水平及文献数据。
主要发现
- miRNA纵向表达高度不一致,且与CA125动态无关。
- 新辅助治疗期间miRNA变化与RECIST肿瘤反应或IDS结局无关联。
- 单变量检验中miR-34a-5p下降与PFS获益相关(p=.009),miR-93-5p下降与OS获益相关(p<.001)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: MicroRNAs (miRNAs) are promising biomarkers in ovarian cancer. Their kinetics during treatment might be useful for monitoring disease burden, and guiding treatments in patients treated with peri-operative chemotherapy and interval debulking surgery (IDS). METHODS: Serial blood samples of patients enrolled in the randomized phase II CHIVA trial, comparing first line carboplatin-paclitaxel +/- nintedanib (NCT01583322) and IDS, were investigated to assess the kinetics of 11 relevant miRNAs. Their prognostic/predictive values regarding the likelihood of complete IDS, and the patient survival, were assessed and compared to those of CA125 kinetics. The selection of the miRNAs (miR-15b-5p, miR-16-5p, miR-20a-5p, miR-21-5p, miR-93-5p, miR-122-5p, miR-150-5p, miR-195-5p, miR-200b-3p, miR-148b-5p and miR-34a-5p) was based on the expression levels found with a large explorative panel, and on the literature data. RESULTS: 756 serial blood samples from 119 patients were analyzed for a total of 8172 miRNA assays, and 1299 CA125 values. The longitudinal kinetics of the miRNA expressions were highly inconsistent, and were not related to CA125 dynamics. The miRNA changes during neoadjuvant treatment were not found associated with RECIST tumor response or IDS outcomes. Decreases of miR-34a-5p and miR-93-5p were associated with PFS benefit (p = .009) and OS benefits (p < .001), respectively, using univariate tests. CONCLUSIONS: The longitudinal kinetics of miRNA expressions during neoadjuvant treatment in ovarian cancer patients were inconsistent, and were not found to be associated with tumor burden changes. Although some prognostic value could be discussed, no predictive value regarding tumor responses or IDS quality could be identified.
引用
- Robelin P, Tod M, Colomban O, et al. Comparative analysis of predictive values of the kinetics of 11 circulating miRNAs and of CA125 in ovarian cancer during first line treatment (a GINECO study). Gynecol Oncol. 2020. PMID: 32712155. doi:10.1016/j.ygyno.2020.07.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。